Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Dermatology Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global dermatology drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Acne, Alopecia, Atopic Dermatitis, Malignant Melanoma, Psoriasis, and Rosacea.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Dermatology Drug Pipeline Insights

- Acne Drug Pipeline Insights

- Alopecia Drug Pipeline Insights

- Atopic Dermatitis Drug Pipeline Insights

- Malignant Melanoma Drug Pipeline Insights

- Psoriasis Drug Pipeline Insights

- Rosacea Drug Pipeline Insights

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.